Twist Bioscience (TWST) Operating Leases (2019 - 2026)

Twist Bioscience (TWST) has reported Operating Leases for 8 consecutive years, with $95.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases rose 47.27% year-over-year to $95.8 million; the TTM figure through Mar 2026 stood at $95.8 million (up 47.27% YoY), while the FY2025 annual figure was $61.8 million, down 12.06% from the prior year.
• Operating Leases declined to $95.8 million in Q1 2026 per TWST's latest filing, from $98.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $98.0 million in Q4 2025 and bottomed at $61.8 million in Q3 2025.
• Historically, Operating Leases has averaged $79.1 million across 5 years, with a median of $79.2 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Leases soared 258.13% — and 2025, when it decreased 28.14%.
• Twist Bioscience's Operating Leases stood at $79.7 million in 2022, then decreased by 3.36% to $77.1 million in 2023, then increased by 7.2% to $82.6 million in 2024, then gained by 18.68% to $98.0 million in 2025, then fell by 2.25% to $95.8 million in 2026.
• Business Quant data shows TWST's Operating Leases at $95.8 million in Q1 2026, $98.0 million in Q4 2025, and $61.8 million in Q3 2025.